HYBRID EVENT: You can participate in person at Rome, Italy or Virtually from your home or work.

2nd Edition of International Conference

and Expo on Clinical Microbiology

June 23-24, 2023 | Rome, Italy

ICCM 2023

Saiema Ahmedi

Speaker at and Expo on Clinical Microbiology 2023 - Saiema Ahmedi
Senior Research Fellow, Department of Biosciences, Jamia Millia Islamia, New Delhi, India, India
Title : Limonene inhibits virulence related traits in Candida albicans


Multidrug resistance and high toxicity towards conventional antifungal drugs is causing serious concern worldwide. Exploration of novel compounds with immense therapeutic potential is required. The present study evaluates the antifungal potential of limonene, a secondary metabolite found in several citrus plants based essential oils. In-vitro anti-Candida studies were performed including haemolysis assay, antifungal susceptibility, secretion of hydrolytic enzymes, morphological transition, adhesion and biofilm formation. Further validation was done by in-silico studies using docking tools followed by MD simulations with five major virulence associated antifungal targets (Als3, Bcr1, Plb1, Sap2 and Tec1). With MIC of 300 μg/ml, it causes only 1% RBC cell lysis. Limonene significantly reduced adhesion to buccal epithelial cells. At MIC, hydrolytic enzymes proteinases and phospholipases was also reduced by 73% and 53% respectively. Limonene treatment inhibits morphological transition in C. albicans which was monitored microscopically. Adhesion and biofilm formation was also reduced by 91% and 87% respectively. Docking and MD simulation studies confirm stable hydrophobic interactions with all the target proteins except Bcr1. Present study suggests that limonene inhibits major virulence factors in C. albicans. Due to low toxicity, easy availability and high antifungal potential, limonene is a suitable candidate to be explored as an antifungal drug. Present work needs to be corroborated with molecular and in vivo studies to understand its mode of action and exact target sites.


Currently, I am working on deciphering the antifungal activity of selected natural compounds and study their mechanistic mode of action against human fungal pathogen Candida albicans. I have employed variety of biochemical and molecular biology techniques to find potential drug targets in Candida.